Oral administration of the selective GPR120/FFA4 agonist compound A is not effective in alleviating tissue inflammation in mouse models of prototypical autoimmune diseases.

MLA

Wannick, Melanie, et al. “Oral Administration of the Selective GPR120/FFA4 Agonist Compound A Is Not Effective in Alleviating Tissue Inflammation in Mouse Models of Prototypical Autoimmune Diseases.” Pharmacology Research & Perspectives, vol. 6, no. 6, Dec. 2018, p. 1–N.PAG. EBSCOhost, https://doi.org/10.1002/prp2.438.

APA

Wannick, M., Bezdek, S., Guillen, N., Thieme, M., Meshrkey, F., Mousavi, S., Seeling, M., Nimmerjahn, F., Mócsai, A., Zillikens, D., Sezin, T., & Sadik, C. D. (2018). Oral administration of the selective GPR120/FFA4 agonist compound A is not effective in alleviating tissue inflammation in mouse models of prototypical autoimmune diseases. Pharmacology Research & Perspectives, 6(6), 1–N.PAG. https://doi.org/10.1002/prp2.438

Chicago

Wannick, Melanie, Siegfried Bezdek, Nathalie Guillen, Markus Thieme, Fibi Meshrkey, Sadegh Mousavi, Michaela Seeling, et al. 2018. “Oral Administration of the Selective GPR120/FFA4 Agonist Compound A Is Not Effective in Alleviating Tissue Inflammation in Mouse Models of Prototypical Autoimmune Diseases.” Pharmacology Research & Perspectives 6 (6): 1–N.PAG. doi:10.1002/prp2.438.